No Detail Found!

Bexarotene monotherapy for patient with refractory early stage mycosis fungoides.

Author(s)
Husein Husein-Elahmed Department of Dermatology, San Cecilio University Hospital, Granada, Spain
Maria-Teresa Gutierrez-Salmerón Department of Dermatology, San Cecilio University Hospital, Granada, Spain
Jose Aneiros-Cachaza Department of Pathology, San Cecilio University Hospital, Granada, Spain
Valentín Garcia-Mellado Department of Dermatology, Virgen de las Nieves University Hospital, Granada, Spain
Abstract
Mycosis fungoides (MF) is a subtype of cutaneous T-Cell lymphoma and oftenly difficult to treat. We report a case of mycosis fungoides in which several lines of therapy were employed including both skin-directed and systemic treatment strategies with no clinical remission. This case highlights MF’s insidious onset. In this patient, the early stage of disease was marked by erythematous plaque and misdiagnosed as tinea corporis. The lack of symptomatic control led to biopsy of the lesion, which in turn precipitated the accurate diagnosis of MF. Several lines of treatment were initiated with unsatisfactory outcomes. Bexarotene therapy was started and good clinical and histological response was observed. We conclude bexarotene as salvage therapy is an efficacious therapeutic option for this patient with plaque mycosis fungoides and its safety profile is favorable for longterm use.
Publication Details
Page(s) 348-350
DOI DOI not available
Published Journal: Journal of Pakistan Association of Dermatologists, Volume: 24, Issue: 4, Year: 2014

Request the full text from PASTIC

0

Citations

0

Downloads

31

Views